MPS Ltd reports record EBITDA of ₹236 crore in FY26, skips dividend
- EBITDA reached ₹236 crore with a 30.7% margin in FY26
- PAT grew 16.3%, lifting EPS to a record ₹102.11
- Final dividend skipped to fund Unbound Medicine acquisition
- Research and Education businesses grew 17% and 29% respectively
- Shareholders approved re-appointment of directors and auditors

*this image is generated using AI for illustrative purposes only.
MPS Limited delivered its most profitable year on record in FY26, with EBITDA reaching approximately ₹236 crore and a margin of 30.7%. The company’s Profit After Tax (PAT) grew by 16.3%, driving earnings per share to a record ₹102.11.
The 56th Annual General Meeting was held on September 4, 2026, via Video Conferencing. Chairman and CEO Rahul Arora highlighted that the Research business grew by approximately 17% while the Education business expanded by nearly 29%. Return on Capital Employed stood at 38.2%.
Strategic Acquisitions And Capital Allocation
The Board did not recommend a final dividend for FY26. Capital was deployed towards the acquisition of Unbound Medicine and other opportunities under evaluation. This marks a shift from the preceding eight years, during which the company returned more than ₹650 crore to shareholders.
What the Numbers Show
The decision to forgo a dividend despite record profitability underscores a strategic pivot towards organic growth via M&A. With EBITDA margins holding steady at 30.7% while PAT grew 16.3%, the operational efficiency remains robust, allowing the firm to fund acquisitions internally without diluting equity or increasing leverage significantly.
Governance And Resolutions
Shareholders approved five resolutions during the meeting. Ordinary business included adopting the audited standalone and consolidated financial statements for the year ended March 31, 2026.
Key governance appointments included:
- Re-appointment of Ms. Jayantika Dave as Non-Independent Non-Executive Director.
- Re-appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for five years.
- Appointment of Mr. Atul Vohra as Non-Independent Non-Executive Director.
- Re-appointment of Mr. Karthik Bhat Khandige as Independent Non-Executive Director.
The Statutory Auditors’ Report and Secretarial Auditors’ Report contained no qualifications or adverse observations. The meeting concluded with e-voting results to be declared within two working days.
Historical Stock Returns for MPS
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.46% | -0.05% | -4.03% | +81.90% | +18.42% | +276.99% |
How will the acquisition of Unbound Medicine specifically integrate with MPS's existing Research business to drive the targeted 17% growth rate?
What is the expected timeline for MPS to resume dividend payouts, and what financial metrics will trigger a return to shareholder distributions?
Given the 29% expansion in the Education business, what new product lines or market segments are driving this outperformance compared to the Research segment?


































